Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
P/E ratio for Beam Therapeutics Inc. (BEAM)
P/E ratio as of 2023: -15.85
According to Beam Therapeutics Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -15.85. At the end of 2022 the company had a P/E ratio of -10.39.
P/E ratio history for Beam Therapeutics Inc. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -15.85 |
| 2022 | -10.39 |
| 2021 | -14.99 |
| 2020 | -14.88 |
| 2019 | -12.27 |
| 2018 | -5.72 |
| 2017 | -30.35 |